BridgeBio Pharma Inc . (NASDAQ:BBIO) reported Q4 EPS of ($0.92), $0.07 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $1.87 million versus the consensus estimate of $5.01 million.
BridgeBio Pharma Inc . (NASDAQ:BBIO) reported Q4 EPS of ($0.92), $0.07 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $1.87 million versus the consensus estimate of $5.01 million.